NICE recommends ezetimibe
The National Institute for Health and Care Excellence (NICE) has published final guidance that recommends ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. The guidance is available from the NICE website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200789
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com